Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, Kojima H, Sobue R, Matsui T, Ino T
Department of Medicine, Fujita Health University School of Medicine.
Rinsho Ketsueki. 1994 Jul;35(7):635-41.
Seventeen patients with refractory or relapsed, intermediate or high grade non-Hodgkin's lymphoma (NHL) were treated with the combination of dexamethasone (40 mg/body x 3d, iv) (DeVIC) between January and December 1992. The treatments were repeated every three weeks for a minimum of two courses unless the patient had PD. G-CSF (2 micrograms/kg, sc) was given during leukopenia in most cases. Of 16 evaluable patients 6 (38%) achieved a complete remission (CR) and 4 showed a partial remission. With median follow up of 15 (7-26) months (mos.) all CR patients were alive in CR, except for 1 patient who died of secondary AML. The actuarial 50% survival duration after DeVIC was 15+ mos. One patient died of sepsis but myelosuppression was generally moderate and no other serious toxicity was observed. Although this is a preliminary study, DeVIC regimen seems to be an effective salvage therapy for patients with refractory or relapsed NHL with acceptable toxicity.
1992年1月至12月期间，17例难治性或复发性中、高度非霍奇金淋巴瘤（NHL）患者接受了地塞米松（40mg/体×3天，静脉注射）联合治疗（DeVIC）。除非患者出现疾病进展（PD），否则每三周重复治疗，至少进行两个疗程。大多数情况下，在白细胞减少期间给予粒细胞集落刺激因子（G-CSF，2μg/kg，皮下注射）。16例可评估患者中，6例（38%）达到完全缓解（CR），4例显示部分缓解。中位随访15（7-26）个月，除1例死于继发性急性髓系白血病（AML）外，所有CR患者均存活于CR状态。DeVIC治疗后50%的精算生存时间为15个月以上。1例患者死于败血症，但骨髓抑制一般为中度，未观察到其他严重毒性。尽管这是一项初步研究，但DeVIC方案似乎是一种对难治性或复发性NHL患者有效的挽救治疗方法，且毒性可接受。
